Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
prolong ejaculation.
Popular Articles

Older Kidney Transplant Patients Should More Often Consider Live Donors
Almost half of kidney transplant candidates older than 60 who are put on the waiting list for a deceased-donor organ will die before getting a transplant, according to new findings from the University of Florida, Cleveland Clinic and Case Western Reserve University.
generic viagra
Swiss Initiative In Systems Biology Launches New Projects
In the second call for proposals, projects focus on either the development of new technologies or on the interface between biomedical research and genomics. The Swiss National Science Foundation (SNSF) approved six RTD-projects today. They will engage a total of 47 research groups from both Swiss Federal Institutes of Technology (ETH Zurich und EPF Lausanne), as well as from the Universities of Basel, Lausanne, Geneva and Zurich. The Friedrich-Miescher Institute of the Novartis Research Foundation is also represented as the only privately financed institution. Eight groups belong simultaneously to one of the above-mentioned universities and to the Swiss Institute for Bioinformatics.
News of the day
Genomic Health Study Shows Breast Cancers In Men Display Very Similar Gene Signatures To Those In Women
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from a study which summarized the gene signatures identified by the Oncotype DX(R) breast cancer test in a large number of male patients for whom the test was used to guide treatment with chemotherapy. The results, which will be presented in a poster presentation on Monday, June 1 (1:00 - 5:00 p.m. ET) at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, demonstrated that breast cancer in men displays similar gene signatures to female breast cancer.
Diagnostics

Inovio Biomedical Universal Dengue DNA Vaccine Demonstrates Strong Immune Responses Against All Four Serotypes

Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that the company"s first SynCon™ dengue virus DNA vaccine induced neutralizing antibody responses against all four distinct serotypes of dengue viruses that are transmitted to humans by mosquitoes. Currently there is no commercially available vaccine or antiviral drug against dengue virus infections. The results were published in Vaccine, July 3, 2009, in a paper entitled, "Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes" (Ramanathan MP, Kuo YC, Selling BH, Li Q, Sardesai NY, Kim JJ, Weiner DB). Dengue fever is the most important mosquito-borne viral disease affecting humans. Its global distribution is comparable to that of malaria and an estimated 2.5 billion people (WHO) live in areas at risk for epidemic transmission, with 50 million cases of dengue infection worldwide every year. The disease is now epidemic in more than 100 countries and has become a focus of vaccine development as an underserved disease. Previous vaccine studies have demonstrated that partial or incomplete protection against only one or more of the four subtypes contributes to increased severity of disease if infected with the other subtypes. Therefore, a major challenge in dengue vaccine development is to protect against all four dengue subtypes simultaneously. Inovio scientists used the SynCon™ approach to develop a universal dengue vaccine. The candidate vaccine is delivered as a single DNA plasmid construct containing sequences of a key surface antigen (domain III) from the E protein of all four subtypes of the dengue virus. In mice studies, the scientists found that this universal vaccine was able to induce cross-protective neutralizing antibody responses against all four dengue subtypes. Dr. J. Joseph Kim, Inovio"s CEO, said, "Dengue fever represents a clear unmet need because it is endemic in many regions of the world and has pandemic potential. Yet it has been a difficult target for vaccine development because the conventional sub-type-specific vaccine approach only exasperates the problem. We are pleased to see the promising results of our experimental universal vaccine candidate against all four subtypes. These studies further underscore the potential and wide applicability of our SynConTM approach for vaccine development." Inovio"s novel SynCon™ technology enables the company to design DNA-based vaccines with the potential to protect against unmatched sub-types and strains of pathogens. Inovio"s design process synthetically defines antigens and gene sequences common across different viral sub-types or taxonomic groups (families) of diseases such as HIV, HCV, human papillomavirus (HPV), and influenza. Inovio Biomedical Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009